Adaptimmune Therapeutics Plc ADR (ADAP)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

60 JUBILEE AVENUE ABINGDON, OXFORDSHIRE, UNITED KINGDOM OX14 4RX

Adaptimmune Therapeutics Plc is a clinical-stage biopharmaceutical company. The Company develops novel cancer immunotherapy products based on T-cell receptor platform that helps to identify cancer targets. Adaptimmune Therapeutics serves customers worldwide.

Data as of 2020-05-30
Market Cap1.44 Billion Shares Outstanding130.099 Million Avg 30-day Volume4.513 Million
P/E Ratio Dividend Yield EPS-1.32
Price/Sales764.841 Price cash flow ratio30.4 Price free cash flow ratio-10.2
Book Value1.43 Price to Tangible Book3.44 Alpha0.01
Short Interest Ratio % Short Interest to Float R-squared0.038814
BETA1.69429 52-week High/Low12.7699 / 0.709 Stddev0.36703
View SEC Filings from ADAP instead.

View recent insider trading info

Funds Holding ADAP (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ADAP BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

BARRIS PETER J

  • Director
6,420 2020-05-27 0

ZAKS TAL ZVI CHIEF MEDICAL OFFICER

  • Officer
0 2020-05-26 1

ALLEVA LAWRENCE M

6,184 2020-05-19 1

BASKETT FOREST

  • 10% Owner
4,478,913 2020-05-19 1

SANDELL SCOTT D

  • Director
  • 10% Owner
4,452,263 2020-05-19 1

KERINS PATRICK J

  • 10% Owner
4,059,376 2020-05-19 0

FLORENCE ANTHONY A. JR.

  • 10% Owner
2,135 2020-04-09 1

SONSINI PETER W.

  • 10% Owner
7,961,163 2020-04-09 1

MOTT DAVID M

  • Director
541,789 2020-04-09 2

BEHBAHANI ALI

  • 10% Owner
5,937,998 2020-04-03 2

NOBLE JAMES

  • Director
0 2020-04-01 2

WOOD GAVIN CHIEF FINANCIAL OFFICER

  • Officer
0 2020-04-01 2

THOMPSON PETER A.

  • Director
  • 10% Owner
6,767,584 2020-03-19 0

AMADO RAFAEL EVP OF R&D AND CMO

135,962 2020-03-18 1

DUNCAN BARBARA GAYLE

  • Director
0 2020-02-03 1

TAYTON-MARTIN HELEN KATRINA CHIEF BUSINESS OFFICER

  • Officer
0 2020-01-16 2

RAWCLIFFE ADRIAN CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
0 2020-01-16 5

BERTRAND WILLIAM C JR CHIEF OPERATING OFFICER

  • Officer
0 2020-01-16 3

LUNGER JOHN CHIEF PATIENT SUPPLY OFFICER

  • Officer
0 2020-01-16 5

NORRY ELLIOT CHIEF MEDICAL OFFICER

  • Officer
0 2020-01-16 3

ORBIMED ADVISORS LLC

ORBIMED CAPITAL GP V LLC

  • Director
  • 10% Owner
9,619,791 2019-12-11 0

SIGAL CHARLES ELLIOTT

  • Director
0 2019-10-01 1

GARONE MICHAEL INTERIM CFO

  • Officer
0 2019-10-01 1

KERR GILES FRANCIS BERTRAM

  • Director
0 2019-07-02 1

FUREY JOHN

  • Director
0 2019-07-02 1

BARRETT M JAMES

  • Director
0 2019-05-30 0

BINDER-SCHOLL GWENDOLYN KNOWLTON CHIEF TECHNOLOGY OFFICER

  • Officer
2,487 2019-01-14 0

VISWANATHAN RAVI

  • 10% Owner
5,000,000 2018-10-17 0

NEW ENTERPRISE ASSOCIATES 14, L.P.

NEA PARTNERS 14, L.P.

NEA 14 GP, LTD

  • 10% Owner
82,978,668 2018-09-07 0

ORBIMED ADVISORS LLC

ORBIMED CAPITAL GP V LLC

ISALY SAMUEL D

  • Director
941,000 2017-12-08 0

KOLLURI KRISHNA KITTU

  • 10% Owner
5,215,128 2016-12-19 0

WELLER HARRY R

  • 10% Owner
3,490,073 2016-10-31 0

KNOWLES JONATHAN KENNETH CHARLES

  • Director
0 2016-08-11 0

LAING IAN MICHAEL

  • Director
0 2016-08-11 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5
No current insider transactions

Elevate your investments